Rockwell Medical, Inc. to Report Third Quarter 2021 Financial and Operating Results on November 15, 2021

Rhea-AI Summary

Rockwell Medical (Nasdaq: RMTI) announced a conference call scheduled for November 15, 2021, at 4:00 PM ET to discuss its Q3 financial results and operational highlights. Investors can participate by dialing (877) 383-7438 or (678) 894-3975, using conference ID 7697945. A live webcast will be available on the company's website, with an archived version accessible for 30 days post-event. Rockwell specializes in biopharmaceuticals, focusing on iron deficiency treatments and is a major supplier of hemodialysis products in the U.S.

WIXOM, Mich., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, November 15 at 4:00 PM ET to discuss its financial results for the three months ended September 30, 2021, and recent operational highlights.

To access the conference call, please dial (877) 383-7438 (local) or (678) 894-3975 (international) at least 10 minutes prior to the start time and refer to conference ID 7697945. A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

To submit questions in advance, please email your questions to invest@rockwellmed.com.

About Rockwell Medical

Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. The Company is developing FPC for the treatment of iron deficiency in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting, a large and rapidly growing segment of healthcare, and where these patients suffer from chronic diseases associated with high incidence of iron deficiency and anemia. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com.

CONTACTS

Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com

FAQ

What is the date of Rockwell Medical's upcoming conference call?

Rockwell Medical will host its conference call on November 15, 2021.

What time will Rockwell Medical's conference call start?

The conference call will start at 4:00 PM ET.

How can I access the conference call for Rockwell Medical's Q3 results?

You can dial (877) 383-7438 or (678) 894-3975 to access the call, using conference ID 7697945.

Where can I find the live webcast for Rockwell Medical's conference call?

The live webcast will be available under 'Events & Presentations' in the Investor section of Rockwell Medical's website.

What will be discussed during Rockwell Medical's conference call on November 15?

The call will cover the financial results for the three months ended September 30, 2021, and recent operational highlights.

What is the focus of Rockwell Medical's biopharmaceutical products?

Rockwell Medical focuses on transforming treatment for iron deficiency and anemia management.